The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Discover BeOne Medicines' robust Q2 2025 performance, with 42% revenue growth, market leadership in oncology, and raised 2025 guidance.

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...

BAKU, Azerbaijan, August 7. Cooperation in the development of the Baku-Tbilisi-Kars (BTK) railway line was discussed during a ...

Discover the latest advancements in multiple sclerosis (MS) treatment, including innovative therapies and strategies for ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, everyone. Welcome to BeOne Q2 2025 Earnings Call Webcast. [Operator Instructions] At this time, I would like to turn the call over ...

Eli Lilly has shared positive top-line results from a head-to-head study of its non-covalent Bruton’s tyrosine kinase (BTK) ...

A key meeting took place in Baku between Rovshan Rustamov, Chairman of Azerbaijan Railways CJSC (ADY), a subsidiary of AZCON ...

Curis Inc (CRIS) reports progress in lymphoma studies and cost management improvements, despite facing financial constraints ...